To Examine Whether Urinary Partial Oxygen Pressure Measurements Are Indicative of the Postoperative Occurrence of Acute Kidney Injury (AKI) in Individuals Who Have Undergone Liver Transplantation
- Disease/Condition
- Acute Kidney Injury
- Drug/Device/Intervention
- urinary partial oxygen pressure
- Study type
- Observational
- Intervention type
- diagnostic test
- Primary sponsor
- Inonu University
- Phase
- N/A
- Start date
- Nov 06, 2023
- End date
- Jul 15, 2024
- Enrollment
- 98 participants
acute kidney injury
Postoperative acute kidney injury (AKI) is a frequent occurrence among liver transplant
 recipients and results in considerable mortality and morbidity. The delayed increase in
 plasma creatinine levels and its susceptibility to external influences, which are utilized in
 the current diagnostic criteria for AKI, contribute to diagnostic delays. Therefore, numerous
 biomarkers, including KIM-1, NGAL, TIMP-2, and CYSTATIN C in plasma, along with urine partial
 oxygen pressure levels and NGAL, are currently under examination to identify acute kidney
 injury at its early stage. It is well-established that the renal medulla is highly
 susceptible to hypoxia, which may consequently lead to acute kidney injury. A range of
 studies have also demonstrated that urine partial oxygen pressure is capable of providing
 valuable insights into the oxygenation state of the renal medulla. Although urine oxygen
 pressure measurement is not commonly used, unlike blood gas analysis, urine partial oxygen
 pressure measurement dates back to 1964. Research among cardiopulmonary bypass patients
 suggests a correlation between urine partial oxygen pressure data and acute kidney injury.
 Therefore, we hypothesize that monitoring urine partial oxygen pressure levels may offer
 insight into the development of acute kidney injury in liver transplant recipients.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06121167
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06121167 through Pure Global AI's free database. This phase not specified trial is sponsored by Inonu University and is currently Not yet recruiting. The study focuses on Acute Kidney Injury. Target enrollment is 98 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.